Introduction {#s1}
============

Globally, COPD was the third leading cause of death in 2018 and 65 million people have moderate to severe COPD \[[@C1]\]. Furthermore, due to the prediction that global health spending will escalate from US\$10 trillion in 2015 to \$20 trillion in 2040 \[[@C2]\], countermeasures against COPD are thus pressing medical, economic and social issues.

Without reducing intolerable exertional dyspnoea, which is a hallmark, especially of the advanced stage of COPD, improving aerobic capacity and prognosis cannot be achieved. In COPD, exertional dyspnoea is recognised as correlating with dynamic air trapping and mechanical constraints on exertional tidal volume (*V*~T~) expansion, which contribute the wasted ventilation. Given that humans develop exertional dyspnoea and a string of studies reported that exertional dyspnoea in COPD was associated with progressive mechanical constraints on *V*~T~ irrespective of the presence of dynamic hyperinflation \[[@C3]--[@C5]\], achieving the ability to expand *V*~T~ to obtain enough ventilation is extremely interesting as a treatment goal for COPD. Traditionally, as the stage of COPD advances, it has been recognised that, with rapid and shallow breathing, that is, with a lower *V*~T~, a higher breathing frequency (*f*~R~) is required during exercise \[[@C6]\]. In fact, however, it is found that most such patients breathe slowly and shallowly with prolonged expiration during exercise. Both breathing patterns should be distinguished to select therapeutic approaches.

Inspiratory pressure load training (IPT), which has been extensively studied as inspiratory muscle training, has been recommended as a pulmonary rehabilitation (PR) programme. Several reviews suggested the effects of IPT as a stand-alone therapy, but, at least in advanced patients with COPD, no large studies have reported the adjunctive effects of IPT when added to PR \[[@C7]--[@C10]\]. In contrast, most reports related to expiratory pressure load training (EPT), known as expiratory muscle training, have investigated the expulsive effort, including sputum \[[@C11]\], perhaps because most EPT devices could provide a low-pressure load alone. Furthermore, W[einer]{.smallcaps} *et al.* \[[@C12]\] reported that the effects of EPT added to IPT were not obtained in severe and very severe COPD. Therefore, the clue to investigate EPT has not been obtained in patients with COPD.

In our previous report, the hypothesis was formulated that EPT could be more effective in COPD patients when prolonged expiration patterns are confirmed by a decreased ratio of inspiratory time to total respiratory cycle time (*T*~I~/*T*tot) during exercise, whereas IPT could be more effective when nonprolonged expiration patterns are confirmed by increased exertional *T*~I~/*T*tot \[[@C13]\]. To improve exercise performance of COPD patients with better exertional *T*~I~/*T*tot, 1) in the prolonged expiration patterns, a larger expiratory *V*~T~ (*V*~T~ex) and a higher mean expiratory flow (*V*~T~ex/expiratory time (*T*~E~)) by EPT might be needed, although based on the Bernoulli principle, pursed-lip breathing needs the low expiratory flow and prolonged expiratory time to reduce airway collapse \[[@C14]\], and 2) in nonprolonged expiration patterns, the larger inspiratory *V*~T~ (*V*~T~in) and higher mean inspiratory flow (*V*~T~in/inspiratory time (*T*~I~)) obtained by IPT might be needed.

Ghrelin has two forms including des-acyl ghrelin and acyl ghrelin; the latter is considered the major active form that has various physiological effects \[[@C15]\]. Edible medium-chain triglycerides (MCTs) change des-acyl ghrelin to acyl ghrelin \[[@C16]\]. Especially in patients with more advanced COPD, if the programme using IPT or EPT results in excessive training, and leads to a cachectic condition, edible MCTs might improve or maintain the patient\'s condition.

This open-label pilot study was conducted to prove the above hypothesis. The efficacy and safety of EPT or IPT with MCT administration were investigated in COPD patients, who were categorised according to their prolonged expiration pattern assessed by *T*~I~/*T*tot during cardiopulmonary exercise testing (CPET).

Material and methods {#s2}
====================

Study design and patients {#s2a}
-------------------------

Patients with moderate and very severe COPD were recruited in the National Hospital Organization Osaka Toneyama Medical Center from February 2018 to August 2019. Patients whose exertional *T*~I~/*T*tot decreased (resting *T*~I~/*T*tot\>peak *T*~I~/*T*tot) received 12-week EPT, while those whose exertional *T*~I~/*T*tot increased (resting *T*~I~/*T*tot≤peak *T*~I~/*T*tot) received 12-week IPT. Nutritional treatment with MCTs was given along with both training programmes.

This prospective study was conducted according to the Declaration of Helsinki and the Good Clinical Practice guidelines, was approved by the ethics committees of our centre (approval number, TNH-2018007) and was registered with the University Hospital Medical Information Network in Japan: <https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035288>, number: UMIN000030937. All patients gave their written informed consent.

The inclusion criteria were as follows: 1) moderate to very severe COPD based on spirometry: post-bronchodilator forced expiratory volume in 1 s (FEV~1~)/forced vital capacity (FVC) ratio \<0.7, and FEV~1~ percent predicted normal \<80% with modified British Medical Research Council: grade 1 and higher; 2) in a stable condition and able to tolerate CPET to ensure adequate evaluation; 3) aged between 40 and 85 years; and 4) provision of a signed agreement to participate in this study. Participants were excluded for any of the following reasons: 1) malignant tumours; 2) active infection; 3) severe heart disease; 4) asthma; 5) change in the drug regimen during this study; 6) receiving PR; 7) receiving oxygen therapy at rest; 8) on therapy for diabetes mellitus or with a glycated haemoglobin level \>7.0%; and 9) judged by the physician to be inappropriate to participate in this study.

Interventions {#s2b}
-------------

### Respiratory pressure load training {#s2b1}

All patients received the training (30 times a set, two sets a day) for 12 weeks at home. The training load was started at 20% of the maximum expiratory pressure (MEP) or maximum inspiratory pressure (MIP) at baseline. If possible, the level was increased once every 2 weeks up to 50% of the maximum pressure. The EMST150 (Aspire Products, Atlanta, GA USA) and the POWERbreathe Medic plus (POWERbreathe International, Stratford Upon Avon, UK) were used for EPT and for IPT, respectively. Details are in the [supplementary material](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00041-2020.figures-only#fig-data-supplementary-materials).

### MCT administration {#s2b2}

Edible oil containing octanoic acid (C8) and decanoic acid (C10) (The Nisshin OilliO Group, Tokyo, Japan) was given at a dose of 2.5 g daily, orally, for 12 weeks.

Evaluation {#s2c}
----------

Pulmonary function tests were done, as previously described \[[@C13], [@C17]\]. Symptom-limited exercise tests were conducted on an electrically-braked cycle ergometer (CV-1000SS, Lode, Groningen, The Netherlands), using a CPET system (Marquette CASE series T 2001, GE Healthcare, Tokyo, Japan; Aero monitor AE310S, Minato Medical Science Co., Ltd, Osaka, Japan), as previously described \[[@C13], [@C18]\]. An incremental exercise test (ET), which consisted of 2-min increments to 10 W, was performed until patient exhaustion without encouragement, especially during exercise. The constant work rate exercise test (WRET) was performed at 70% of the peak workload in the incremental ET before treatment. All patients were asked to maintain a cycle ergometer speed of about 60 rpm while looking at the rpm meter. Minute ventilation (*V′*~E~), oxygen uptake (*V′*~O~2~~), carbon dioxide output (*V′*~CO~2~~), *f*~R~, *V*~T~in, *V*~T~in/*T*~I~, *V*~T~ex, *V*~T~ex/*T*~E~, *T*~I~/*T*tot, physiologic dead space/tidal volume ratio (*V*~D~/*V*~T~), and O~2~ pulse (*V′*~O~2~~/heart rate (HR)) were measured breath by breath and collected as 30-s average values at rest, during exercise at 2-min intervals and at the end of exercise. The anaerobic threshold (AT) was identified using the V-slope method and the nadir of the parameter *V′*~E~/*V′*~O~2~~ was measured during exercise. The severity of dyspnoea, intensity of leg fatigue and percutaneous oxygen saturation (*S*~pO~2~~) were evaluated by the modified Borg scale \[[@C19]\] at rest and during the last 15 s of each exercise stage and at the end of exercise. *V*~T~in−*V*~T~ex was evaluated as the volume of air remaining in the lung after expiration. Iso-time was defined as the highest equivalent exercise time for each subject among three evaluations. Dual-energy radiography absorptiometry and respiratory muscle strength evaluation by the MIP and MEP, respectively were performed as described previously \[[@C13], [@C20]\]. The validated Japanese version of the St. George\'s Respiratory Questionnaire (SGRQ) was used as described previously \[[@C16], [@C21], [@C22]\].

Outcome measures {#s2d}
----------------

### Efficacy {#s2d1}

The primary outcomes was the exertional change in *T*~I~/*T*tot. The secondary outcomes included: 1) the SGRQ score; 2) CPET parameters (peak *V′*~O~2~~, endurance time and dyspnoea intensity (Borg scale)); and 3) MEP and MIP.

### Safety {#s2d2}

All participants were included in the safety analyses.

Sample size and statistical analysis {#s2e}
------------------------------------

At the time of the study design, no studies had investigated the efficacy of EPT or IPT in COPD patients based on the exertional prolongation of expiration by *T*~I~/*T*tot. As this study protocol has never been previously performed, the sample size could not be calculated. This open-label pilot study evaluated at least 10 participants each for EPT and IPT.

The effects of the intervention were examined twice (*i.e.* at Week 6 and Week 12) and were analysed in only each group. When no evaluations in the outcome were performed at Week 6, the changes between at pretreatment and at Week 12 were analysed using the Wilcoxon signed rank test. The changes during the treatment time course (*i.e.* pretreatment, Week 6 and Week 12) were analysed using a linear mixed-effects model. The least squares means Tukey\'s honestly significant difference test was used for the comparison of each variable among the treatment points \[[@C23]\]. A p-value \<0.05 was considered significant. Statistical analyses were performed using JMP software, version 11 (SAS Institute, Cary, NC, USA).

Results {#s3}
=======

Of the 22 enrolled patients, 21 completed this study protocol, because 1 patient dropped out after enrolment due to having his first episode of bronchial asthma during this study ([figure 1](#F1){ref-type="fig"}). Eleven patients completed the EPT added to MCT administration (EPT group) protocol and 10 completed the IPT added to MCT administration (IPT group) protocol, whose data were used to ensure efficacy using a per-protocol analysis. All patients enrolled in the EPT group had severe to very severe airway obstruction with reduced exercise tolerance and seven patients had a history of PR. The EPT group had a higher frequency of hospitalisation than the IPT group. [Table 1](#TB1){ref-type="table"} shows the patients\' baseline characteristics.

![Trial profile. CPET: cardiopulmonary exercise testing; EPT: expiratory pressure load training; IPT: inspiratory pressure load training; MCT: medium-chain triglycerides; *T*~I~/*T*tot: the ratio of inspiratory time to total respiratory cycle time.](00041-2020.01){#F1}

###### 

Baseline characteristics of the patients (n=21)

                                                **EPT group (n=11)**   **IPT group (n=10)**  **p-value**
  -------------------------------------------- ---------------------- ---------------------- -------------
  **Age years**                                       67.3±5.3               73.4±4.6        0.1111
  **Sex male/female n**                                 10/1                   10/0          0.3286
  **BMI kg·m^−2^**                                    20.7±2.5               20.8±3.5        1.0000
  **Cigarette smoking pack-years**                   62.0±26.9              70.2±29.0        0.7245
  **GOLD, II/III/IV n**                                0/7/4                  4/5/1          0.0346
  **Pulmonary function test**                                                                
   FEV~1~ L                                          0.87±0.19              1.18±0.40        0.1486
   FEV~1~ % predicted                                 32.8±7.0              45.1±14.2        0.0448
   FEV~1~/FVC %                                       33.9±6.0               38.9±6.5        0.1130
   VC L                                              2.75±0.56              3.14±0.80        0.2048
   VC % predicted                                    84.8±12.3              98.0±22.8        0.0980
  **Incremental work rate exercise testing**                                                 
   Peak *V′*~O~2~~ mL·min^−1^·kg^−1^                  10.7±2.7               11.6±3.4        0.5968
   AT mL·min^−1^·kg^−1^                               8.8±1.9                10.8±2.0        0.0736
  **Medications n**                                                                          
   LAMA/LABA/ICS                                      10/11/8                10/10/4         0.6321
   Triple inhalation therapy                             8                      4            0.1301
   Long-term oxygen therapy^\#^                          3                      2            0.6959
   History of pulmonary rehabilitation                   7                      4            0.2787
   History of hospitalisation                            8                      2            0.0157

Data are presented as mean±[sd]{.smallcaps}, unless otherwise stated. EPT: expiratory pressure load training; IPT: inspiratory pressure load training; BMI: body mass index; GOLD: global initiative for chronic obstructive lung disease; FEV~1~: forced expiratory volume in 1 s; FVC: forced vital capacity; VC: vital capacity; AT: anaerobic threshold; *V'*~O~2~~: oxygen uptake; LABA: long-acting β~2~-agonist; LAMA: long-acting muscarinic antagonist; ICS: inhaled corticosteroids. Triple inhalation: a combination of LAMA, LABA and ICS. Medications are presented separately. ATs were not detectable in four patients in the EPT group, and in three patients in the IPT group. History of hospitalisation owing to a deteriorated condition in relation to COPD was investigated. ^\#^: All patients used long-term oxygen therapy only on exertion.

EPT and IPT progression {#s3a}
-----------------------

The ratio of the attained pressure after the 12-week programme to the target pressure was 78%±19% in the EPT group and 95%±16% in the IPT group.

Evaluation in the EPT group {#s3b}
---------------------------

Only MEP increased during the whole EPT treatment course ([table 2](#TB2){ref-type="table"}).

###### 

Changes at peak exercise in the incremental exercise parameters and resting respiratory muscle strength after respiratory pressure load training

                                      **EPT group (n=11)**     **p-value**      **IPT group (n=10)**   **p-value**                                                     
  ---------------------------------- ---------------------- ------------------ ---------------------- ------------- ------------- ------------- ---------------------- --------
  **Maximum workload W**                   35.5±15.7           40.9±13.8\*        44.5±13.7\*\*\*        0.0005       43.0±15.7     47.0±17.7       49.0±19.1\*\*       0.0096
  ***V′*~O~2~~ mL·min^−1^**               613.9±199.2          639.5±223.0        670.2±233.2\*\*        0.0025      646.0±220.9   657.6±243.7   694.5±255.7\*\*^,\#^   0.0091
  ***V′*~O~2~~ mL·min^−1^·kg^−1^**          10.7±2.7             11.2±3.1           11.6±3.1\*\*         0.0028       11.6±3.4      11.7±3.7       12.4±3.9\*^,\#^      0.0072
  ***V′*~E~ L·min^−1^**                     27.9±7.0             29.1±7.3          30.1±8.3\*\*\*        0.0006       30.1±8.5      30.8±9.8         32.3±11.0\*        0.0147
  ***V*~T~ex mL**                           998±232              1061±207            1073±222\*          0.0418       1104±259      1055±287           1104±310         0.3443
  ***f*~R~ breaths·min^−1^**                  28±5                 28±5                 29±5             0.3215         28±5          29±7              31±8\*          0.0164
  ***V′*~E~/*V′*~O~2~~**                    46.5±4.8             46.7±6.3             46.1±5.6           0.7966       48.3±8.4      48.8±10.5          47.7±8.3         0.4216
  ***V′*~E~/*V′*~CO~2~~**                   47.0±5.7             46.8±6.8             46.2±6.6           0.7626       48.6±9.7      48.4±11.0          47.9±9.6         0.7709
  ***V*~D~/*V*~T~**                        0.42±0.04            0.41±0.04            0.41±0.04           0.2974       0.41±0.05     0.41±0.05         0.41±0.05         0.8071
  **HR beats·min^−1^**                       119±13               120±12              125±12\*           0.0142        113±15        117±19             117±17          0.4643
  **O~2~ pulse mL·beats^−1^**               5.1±1.3              5.3±1.5              5.3±1.5            0.3072        5.8±1.7       5.5±1.7           5.6±1.7          0.2675
  ***S*~pO~2~~** **%**                        89±5                 89±4                 88±4             0.1970         91±4          89±4               91±4           0.1433
  **Dyspnoea Borg scale**                   6.3±2.6              6.0±2.6              6.7±2.0            0.1768        6.3±1.8      7.5±1.9\*        7.8±1.5\*\*        0.0040
  **Leg discomfort Borg scale**             4.2±3.7              4.9±3.5              6.2±2.2            0.0867        5.5±1.5     6.8±1.9\*\*      7.2±1.5\*\*\*       0.0002
  ***V*~T~in/*T*~I~ mL·s^−1^**              1524±407             1523±322             1600±413           0.1450       1318±248      1346±274           1374±328         0.3770
  ***V*~T~ex/*T*~E~ mL·s^−1^**              651±169             706±202\*           728±217\*\*          0.0025        820±276       847±334          884±365\*         0.0347
  ***V*~T~in − *V*~T~ex mL**                 25±44                 5±19                1±26\*            0.0339         2±26          0±44              −15±40          0.2506
  ***T*~I~/*T*tot peak − rest**            −0.04±0.06        −0.00±0.02\*\*\*      −0.01±0.03\*\*        0.0001       0.04±0.02     0.02±0.04         0.02±0.03         0.5356
  **MEP cmH~2~0**                          125.4±24.7          149.2±33.0\*        153.4±32.4\*\*        0.0047      114.9±45.4    110.5±40.7         117.9±47.1        0.5943
  **MIP cmH~2~0**                          77.9±19.3            81.2±20.2            85.9±21.8           0.1530       67.9±17.2     74.2±17.4        78.0±19.0\*        0.0217

Data are presented as mean±[sd]{.smallcaps}. EPT: expiratory pressure load training; IPT: inspiratory pressure load training; *V′*~O~2~~: oxygen uptake; *V′*~E~: minute ventilation; *V*~T~ex: expiratory tidal volume; *f*~R~: breathing frequency; *V′*~CO~2~~: carbon dioxide output; *V*~D~/*V*~T~: physiologic dead space/tidal volume ratio; HR: heart rate; O~2~ pulse: *V′*~O~2~~/HR; *S*~pO~2~~: percutaneous oxygen saturation; *T*~I~: inspiratory time; *V*~T~in: inspiratory tidal volume; *T*~E~: expiratory time; *T*~I~/*T*tot: inspiratory duty cycle; MEP: maximal expiratory pressure; MIP: maximal inspiratory pressure. \*: p\<0.05; \*\*: p\<0.01; \*\*\*: p\<0.001, by the least squares means Tukey honestly significant difference, compared with the pretreatment; ^\#^: p\<0.05, by the least squares means Tukey\'s honestly significant difference, compared with the values after 6 weeks of IPT.

Changes at peak exercise in the incremental ET for 12 weeks are shown in [figure 2a](#F2){ref-type="fig"}−e and [table 2](#TB2){ref-type="table"}. The *V′*~O~2~~ (p=0.0028), *V*~T~ex (p=0.0418), *V*~T~ex/*T*~E~ (p=0.0025), *V*~T~in−*V*~T~ex (p=0.0339) and *T*~I~/*T*tot (peak−rest) (p=0.0001) improved significantly during the whole EPT treatment course. When comparing each parameter among the treatment points, significant improvements compared with pretreatment, which were confirmed at both 6 and 12 weeks, were observed in *V*~T~ex/*T*~E~ and *T*~I~/*T*tot (peak−rest).

![Changes at peak exercise on the incremental exercise testing after expiratory pressure load training (EPT, panels a--e) or inspiratory pressure load training (IPT, panels f--j). *T*~E~: expiratory time; *T*~I~/*T*tot: the ratio of inspiratory time to total respiratory cycle time; *V′*~O~2~~: oxygen uptake; *V*~T~ex: expiratory tidal volume; *V*~T~ex/*T*~E~: mean expiratory flow; *V*~T~in: inspiratory tidal volume; *f*~R~: breathing frequency. By a linear mixed-effect model: p-value. By the least squares means Tukey\'s honestly significant test: \*: p\<0.05, \*\*: p\<0.01, \*\*\*: p\<0.001, compared with the pretreatment, ^\#^:p\<0.05, compared with after 6 weeks of treatment.](00041-2020.02){#F2}

Changes at the limit of tolerance and during exercise on the constant WRET for 12 weeks are shown in [figure 3a](#F3){ref-type="fig"}--c and [tables 3](#TB3){ref-type="table"} and [4](#TB4){ref-type="table"}. The increased endurance time was highly significant (p\<0.0001) and the significance was evident already from 6 weeks. Increased leg fatigue seemed to stop the prolonged exercise obtained from EPT. The exertional dyspnoea was reduced significantly at iso-time ([figure 3b](#F3){ref-type="fig"} and [table 4](#TB4){ref-type="table"}). The *V*~T~ex increased from the early exercise phase ([figure 3c](#F3){ref-type="fig"}) and the *f*~R~ was reduced at iso-time ([table 4](#TB4){ref-type="table"}). FIGURE 3Changes at the limit of tolerance and during exercise on the constant work rate exercise testing after expiratory pressure load training (EPT, panels a--c) or inspiratory pressure load training (IPT, panels d--f). *f*~R~ : breathing frequency; iso-time: highest equivalent exercise time for each subject among three evaluations; *V*~T~ex: expiratory tidal volume. Open circle: pretreatment; closed triangle: after 6 weeks of treatment; closed circle: after 12 weeks of treatment. By a linear mixed-effects model: p-value. By the least squares means Tukey\'s honestly significant test: \*: p\<0.05, \*\*: p\<0.01, \*\*\*: p\<0.001, \*\*\*\*: p\<0.0001, compared with the pretreatment; ^\#^: p\<0.05, compared with after 6 weeks of treatment. TABLE 3Changes at the limit of tolerance in the constant work rate exercise parameters after respiratory pressure load training**EPT group (n=11)p-valueIPT group (n=10)p-valuePretreatmentAfter 6 weeksAfter 12 weeksPretreatmentAfter 6 weeksAfter 12 weeksEndurance time s**481±195699±293\*\*\*824±289\*\*\*\*^,\#^\<0.0001472±197631±344835±481\*\*\*^,\#^0.0004***V′*~O~2~~** **mL·min^−1^**628.3±191.7603.1±171.4614.2±198.90.6749613.7±185.7657.3±182.3611.3±209.70.5825***V′*~O~2~~** **mL·min^−1^·kg^−1^**10.9±2.910.6±2.410.8±2.80.732311.6±2.711.5±2.811.5±3.30.9970***V′*~E~ L·min^−1^**27.6±6.627.2±5.727.6±8.70.932828.1±7.428.6±8.529.2±8.70.5825***V*~T~ex mL**980±2371041±1871038±2290.37371065±2261029±242997±2800.6238***f*~R~ breaths·min^−1^**29±627±527±70.212727±528±630±7\*\*0.0090***V′*~E~/*V′*~O~2~~**44.9±4.646.2±5.345.3±5.10.710546.9±8.245.2±4.849.7±3.6\*0.0565***V′*~E~/*V′*~CO~2~~**47.0±4.546.7±4.546.7±4.70.976849.3±8.946.8±3.951.5±10.70.0649***V*~D~/*V*~T~**0.41±0.030.42±0.040.42±0.040.84000.41±0.050.41±0.040.43±0.05\*0.0389**HR beats·min^−1^**119±14117±13124±120.0780111±15112±16113±160.6717**O~2~ pulse mL·beats^−1^**5.2±1.35.3±1.24.9±1.40.25595.5±4.05.6±1.35.3±1.60.7725***S*~pO~2~~ %**88±588±587±60.238191±490±591±40.2941**Dyspnoea Borg scale**6.5±3.06.6±2.57.0±2.30.55117.0±2.17.9±1.98.5±1.2\*\*0.0058**Leg discomfort Borg scale**4.5±3.45.8±3.26.8±2.6\*\*0.01086.4±2.26.9±2.38.1±1.7\*\*^,\#^0.0061***V*~T~in/*T*~I~ mL·s^−1^**1416±3111495±3151515±4150.36221224±1851264±2531337±2460.1439***V*~T~ex/*T*~E~ mL·s^−1^**682±185677±154683±1990.9548752±222778±279802±3110.3705***V*~T~in − *V*~T~ex mL**15±52−4±43−1±510.31835±37−4±40−8±290.4149***T*~I~/*T*tot peak − rest**−0.04±0.04−0.01±0.040.01±0.030.07700.03±0.030.02±0.050.03±0.030.2959Data are presented as means±[sd]{.smallcaps}. EPT: expiratory pressure load training; IPT: inspiratory pressure load training; *V′*~O~2~~: oxygen uptake; *V′*~E~: minute ventilation; *V*~T~ex: expiratory tidal volume; *f*~R~: breathing frequency; *V′*~CO~2~~: carbon dioxide output; *V*~D~/*V*~T~: physiologic dead space/tidal volume ratio; HR: heart rate; O~2~ pulse: *V′*~O~2~~/HR; *S*~pO~2~~: percutaneous oxygen saturation; *V*~T~in: inspiratory tidal volume; *T*~I~: inspiratory time; *T*~E~: expiratory time; *T*~I~/*T*tot: inspiratory duty cycle. \*: p\<0.05; \*\*: p\<0.01, \*\*\*: p\<0.001; \*\*\*\*: p\<0.0001, by the least squares means Tukey honestly significant difference, compared with the pretreatment; ^\#^: p\<0.05, by the least squares means Tukey\'s honestly significant difference, compared with the values after 6 weeks of EPT or IPT. TABLE 4Changes at iso-time in the constant work rate exercise parameters after respiratory pressure load training**EPT group (n=11)p-valueIPT group (n=10)p-valuePretreatmentAfter 6 weeksAfter 12 weeksPretreatmentAfter 6 weeksAfter 12 weeksIso-time s**474±198460±210***V′*~O~2~~** **mL·min^−1^**627.1±192.3613.4±187.8613.4±203.10.8356611.7±190.3661.9±185.4619.7±185.40.7722***V′*~O~2~~** **mL·min^−1^·kg^−1^**10.9±2.910.8±2.710.8±2.90.910111.0±2.811.6±2.811.1±3.20.9070***V′*~E~ L·min^−1^**27.5±6.627.1±6.727.4±9.30.930627.9±7.628.3±8.428.6±8.80.7461***V*~T~ex mL**981±2371107±195\*1085±2310.03201068±2291088±2711109±2920.7512***f*~R~ breaths·min^−1^**29±625±5\*26±70.020326±526±626±70.9782***V′*~E~/*V′*~O~2~~**44.7±4.445.1±5.445.0±4.80.960346.8±8.244.5±4.647.9±10.20.4200***V′*~E~/*V′*~CO~2~~**46.9±4.246.6±4.546.5±4.30.948149.4±9.546.2±3.949.5±10.40.8722***V*~D~/*V*~T~**0.41±0.030.42±0.040.41±0.030.60590.41±0.040.40±0.040.41±0.050.4720**HR beats·min^−1^**119±13113±13117±140.1541111±16109±15109±130.5981**O~2~ pulse mL·beats^−1^**5.2±1.35.4±1.35.2±1.30.53595.5±1.55.8±1.45.6±1.80.7866***S*~pO~2~~** **%**88±589±589±50.336191±491±492±30.3720**Dyspnoea Borg scale**6.5±3.05.0±3.2\*3.8±2.5\*\*\*0.00036.8±2.46.7±2.15.3±0.60.0576**Leg discomfort Borg scale**3.8±2.84.6±3.33.8±2.80.51406.2±2.56.1±2.15.1±0.80.1027***V*~T~in/*T*~I~ mL·s^−1^**1413±3101417±3191429±4560.97751227±1821197±1931214±2380.3091***V*~T~ex/*T*~E~ mL·s^−1^**680±185671±171\*681±2340.9387746±228795±304778±3060.3705***V*~T~in − *V*~T~ex mL**13±49−13±48−3±290.12745±37−12±42−8±330.1896***T*~I~/*T*tot peak − rest**−0.03±0.05−0.00±0.04−0.01±0.020.15540.02±0.020.06±0.100.05±0.030.3236Data are presented as mean±[sd]{.smallcaps}. EPT: expiratory pressure load training; IPT: inspiratory pressure load training; *V′*~O~2~~: oxygen uptake; *V′*~E~: minute ventilation; *V*~T~ex: expiratory tidal volume; *f*~R~: breathing frequency; *V′*~CO~2~~: carbon dioxide output; *V*~D~/*V*~T~: physiologic dead space/tidal volume ratio; HR: heart rate; O~2~ pulse: *V′*~O~2~~/HR; *S*~pO~2~~: percutaneous oxygen saturation; *V*~T~in: inspiratory tidal volume; *T*~I~: inspiratory time; *T*~E~: expiratory time; *T*~I~/*T*tot: inspiratory duty cycle. \*: p\<0.05; \*\*\*: p\<0.001, by the least squares means Tukey honestly significant difference, compared with the pretreatment.

All SGRQ scores except for the SGRQ symptoms domain improved ([table 5](#TB5){ref-type="table"}). Pulmonary functions and body weight were unchanged ([table 5](#TB5){ref-type="table"}).

###### 

Changes in the resting parameters after respiratory pressure load training

                            **EPT group (n=11)**    **p-value**     **IPT group (n=10)**   **p-value**                
  ------------------------ ---------------------- ---------------- ---------------------- ------------- ------------- --------
  **Body weight kg**              57.2±9.8           57.3±10.1             0.9425           55.2±10.1     55.4±10.2    0.1354
  **Total lean mass kg**          41.9±6.5            41.9±6.5             0.4648           41.2±4.8      37.5±13.6    0.0742
  **Total fat mass kg**           12.0±4.6            12.3±5.1             0.3203           12.1±6.1      11.7±6.1     0.5703
  **MEP cmH~2~O**                125.4±24.7        153.4±32.4\*\*          0.0047          114.9±45.4    117.9±47.1    0.5943
  **MIP cmH~2~O**                77.9±19.3           85.9±21.8             0.1530           67.9±17.2    78.0±19.0\*   0.0217
  **PFT**                                                                                                             
   FEV~1~ L                      0.87±0.19           0.89±0.19             0.3516           1.18±0.40     1.15±0.41    0.1563
   FEV~1~/FVC %                   33.9±6.0            33.4±4.1             0.9648           38.9±6.5      40.0±9.0     0.4316
   %FEV~1~ %                      32.8±7.0            33.8±6.9             0.2500           45.1±14.2     44.0±14.9    0.1602
   VC L                          2.75±0.56           2.83±0.60             0.1758           3.14±0.80     2.98±0.91    0.0605
   %VC %                         84.8±12.3           87.8±13.2             0.1230           98.0±22.8     92.9±26.5    0.0645
   IC L                          1.72±0.21           1.83±0.38             0.1221           2.06±0.52     1.99±0.59    0.5566
   SGRQ symptoms domain          47.4±21.7           43.5±21.0             0.7344           53.8±22.8     56.7±20.2    0.7344
   SGRQ activity domain          66.9±19.1           59.6±19.3             0.0156           56.1±28.5     56.3±26.5    1.0000
   SGRQ impacts domain           34.6±18.2           24.5±18.7             0.0049           25.7±15.9     28.0±21.2    0.7695
   SGRQ total score              46.7±17.2           38.7±18.3             0.0137           38.8±19.8     41.2±21.8    1.0000

Data are presented as mean±[sd]{.smallcaps}. EPT: expiratory pressure load training; IPT: inspiratory pressure load training; MEP: maximal expiratory pressure; MIP: maximal inspiratory pressure; PFT: pulmonary function test; FEV~1~: forced expiratory volume in 1 s; FVC: forced vital capacity; VC: vital capacity; IC: inspiratory capacity; SGRQ: St. George\'s Respiratory Questionnaire. \*: p\<0.05; \*\*: p\<0.01, by the least squares means Tukey\'s honestly significant difference, compared with the pretreatment.

Evaluation in the IPT group {#s3c}
---------------------------

During the whole IPT treatment course: 1) only MIP increased; 2) at peak exercise in the incremental ET during 12 weeks, *V′*~O~2~~ (p=0.0072) and *V′*~E~ (p=0.0147) improved and exertional dyspnoea worsened with increased *f*~R~ and unchanged *V*~T~ex ([figure 2f](#F2){ref-type="fig"}--j and [table 2](#TB2){ref-type="table"}); and 3) on the constant WRET, the increased endurance time was highly significant (p=0.0004). At the limit of tolerance, however, the *f*~R~ and *V*~D~/*V*~T~ were increased with worsened exertional dyspnoea and leg fatigue ([figure 3e](#F3){ref-type="fig"},f and [table 3](#TB3){ref-type="table"}). All SGRQ scores, pulmonary functions and body weight did not improve ([table 5](#TB5){ref-type="table"}).

Safety {#s3d}
------

Loose stools were observed in 2 of the 22 enrolled patients. No treatment-related serious events such as a pneumothorax were reported.

Discussion {#s4}
==========

The main findings of this study were as follows. First, 12-week EPT with MCT administration: 1) improved quality of life (QOL) based on the SGRQ scores, the peak *V′*~O~2~,~ and the endurance time; 2) increased *V*~T~ex and *V*~T~ex/*T*~E~ and decreased *V*~T~in−*V*~T~ex at peak exercise on the incremental ET, which improved prolonged expiration (primary outcome); and 3) increased *V*~T~ex from the commencement of the exercise on the constant WRET and then the exertional dyspnoea was reduced at iso-time. Second, 12-week IPT with MCT administration: 1) did not improve the SGRQ scores, but it improved peak *V′*~O~2~~ and endurance time; and 2) increased the *f*~R~ with increased exertional dyspnoea and without a change of exertional *T*~I~/*T*tot (primary outcome) on the incremental ET and the constant WRET.

It has been considered that training patients with COPD to breathe slowly and deeply for rapid and shallow breathing during exercise, which leads to dynamic hyperinflation, is useful to reduce exertional dyspnoea \[[@C6]\]. However, slow and shallow breathing, instead of rapid and shallow breathing, unexpectedly leads to exertional dyspnoea to stop exercise. N[eder]{.smallcaps} *et al.* \[[@C24]\] reported that, in a study of mild to end-stage COPD including healthy controls, the peak *f*~R~ with the incremental ET decreased to stop exercise as the disease stage advanced. Also, in the present study, reduced *f*~R~ accompanied by reduced *V*~T~ex was confirmed in both groups pretreatment. Moreover, in the EPT group, patients with a more advanced stage than those in the IPT group breathed slowly and shallowly with the exertional prolongation of expiration ([table 2](#TB2){ref-type="table"}). Training such patients using, for example, pursed-lip breathing, would be less useful, because slower breathing might be impossible and ineffective to obtain enough ventilation. Therefore, countermeasures against slow and shallow breathing with prolonged expiration of COPD have largely been effectively overlooked.

On the EPT, the increase in endurance time, measured with the constant WRET, was large. The 5.7-min increase with reduced exertional dyspnoea was long enough, given that: 1) the clinical meaningful difference is 100 s \[[@C18]\]; and 2) patients with severe and very severe COPD and severely reduced exercise tolerance, who had already taken most available treatments including PR enrolment ([table 1](#TB1){ref-type="table"}), all obtained a prolonged endurance time ([figure 3a](#F3){ref-type="fig"}). The adequate aerobic capacity with the improvement in QOL is rewarding. In the EPT group, all treatment differences in the SGRQ total, impact and total scores were more than seven units, which was higher than the four units accepted as clinically relevant \[[@C22]\]. M[ota]{.smallcaps} *et al.* \[[@C25]\] reported that, in severe COPD, 5-week EPT improved the SGRQ scores but not ventilatory variables, including peak *V′*~O~2~~. Their findings are consistent with our results in which the unchanged peak *V′*~O~2~~ was obtained after 6 weeks in the EPT group, suggesting that the duration of EPT needs to be more than 6 weeks. Of note, in the present study, it was demonstrated that the increase of *V*~T~ex/*T*~E~ and the improved prolonged expiration from baseline were confirmed from 6 weeks, but the increase of *V*~T~ex was not significant ([table 2](#TB2){ref-type="table"} and [figure 2](#F2){ref-type="fig"}). These responses might mean that after EPT, even if the *T*~E~ was markedly reduced, enough expiratory volume was obtained without airway collapse. Furthermore, at 12 weeks, a larger *V*~T~ex or higher *V*~T~ex/*T*~E~ obtained from EPT improved exercise performance and exertional dyspnoea in advanced COPD. EPT might thus prevent dynamic wasted ventilation, as the reduced air remaining in the lung after expiration, that is *V*~T~in−*V*~T~ex, on the incremental ET was confirmed. It is unclear, however, where the site of action for EPT is and how EPT affects it. Laryngeal narrowing occurs in humans during the expiratory phase, and as the stage of COPD advances, the larynx narrows more during exercise, and this response is related to longer prolonged expiration, lower *V*~T~ex, and lower peak *V′*~O~2~~ \[[@C26], [@C27]\]. As one of the possible mechanisms of EPT, EPT might promote laryngeal widening by affecting the laryngeal abductors \[[@C27]\], which could prevent the vocal cords with central airways from collapsing during exercise. In the future, observation of glottic function by laryngoscopy during exercise might prove the above possible mechanism.

In IPT, the increased ventilation resulting from rapid *f*~R~ leads to increased aerobic capacity and endurance time. On the constant WRET, [figure 3f](#F3){ref-type="fig"} shows that the *f*~R~ levels were similar at iso-time among all evaluation points, and the slope of *f*~R~ to the endurance time was not changed after IPT. In addition, [tables 3](#TB3){ref-type="table"} and [4](#TB4){ref-type="table"} show that, after IPT, all ventilatory variables were not changed at iso-time, but the increased *f*~R~-related variables (*V*~D~/*V*~T~, *V′*~E~/*V′*~O~2~~ and dyspnoea) were increased at the limit of tolerance. These findings suggest that IPT enabled exercise by forcing greater additional effort than pretreatment levels using the rapid *f*~R~. In fact, after IPT, only one patient with the highest %FEV~1~ among the IPT group could exercise longer, reducing the *f*~R~ with the higher *V*~T~ex. If wasted ventilation does not occur, the rapid *f*~R~ may be attractive for getting enough ventilation, because healthy subjects can reach a rapid *f*~R~ and patients with advanced COPD cannot reach it to stop exercise \[[@C24]\]. After IPT, three patients could not achieve enough prolongation of endurance time ([figure 3d](#F3){ref-type="fig"}) due to the increased *f*~R~-related wasted ventilation. These findings suggested that IPT is not indicated for patients with wasted ventilation. W[einer]{.smallcaps} *et al.* \[[@C12]\] reported that adding IPT to EPT did not show additional effects, although the effect of EPT alone was confirmed. The forcing effort owing to the increased *f*~R~ by IPT might hide the effect of EPT in advanced COPD.

Weight and O~2~ pulse, changes in both of which were attributed to the effect of MCT administration \[[@C16]\], were unchanged in both groups. There was, therefore, little effect of MCT administration.

This study had some limitations. First, further studies are necessary to investigate whether patients without exertional prolongation of expiration are appropriate for EPT. Second, the EMST150 is generally used by singers and athletes. Managing to get a suitable device for EPT, which can accurately select the specified pressure for each COPD patient, is necessary. Third, the profoundly improved exercise performance provided new problems: leg discomfort appeared as an exercise limitation, which required exercise training for the legs. Fourth, the increase of MIP after IPT was low, which might be related to insufficient IPT. Although the increase in endurance time, measured with constant WRET, was large enough with IPT, a suitable regimen for IPT is necessary. Given the useful results obtained, future studies, including randomised controlled trials, should be conducted to develop EPT/IPT.

In conclusion, this study showed the benefits of 12-week EPT and IPT based on the exertional prolonged expiration on aerobic capacity and endurance time in COPD patients. After EPT, a larger *V*~T~ex and higher *V*~T~ex/*T*~E~ reduced the air remaining in the lung after expiration and improved exertional prolongation of expiration, reducing exertional dyspnoea. After IPT, the increased ventilation from the increased *f*~R~ resulted in unchanged breathing timing and worsening of dyspnoea during exercise. Given that both EPT and IPT are inexpensive and can easily be handled by elderly patients, if managing COPD with EPT/IPT is selected appropriately, it could become widespread as home-based training.
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